Amazing for a company that has a one target product and severe competition.
There is nothing unique about Galena's drug product, as it being developed by other companies using similar
chemistry. If Gale ever gets approval, we are looking at 3 years out, and much more dilution. This stock is
a manipulated overpriced equity pinning the hopes of penny stock players. SELL!